An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future

Albert Qin, Raymond W. Urbanski, Lennex Yu, Tasfia Ahmed, John Mascarenhas

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history. Clinical trial data indicate the dose and titration of ropeginterferon alfa-2b is safe and effective. However, additional studies may provide rationale for an amended, higher initial dosage and rapid titration. This article is an overview of current and upcoming studies of ropeginterferon alfa-2b in myeloproliferative neoplasms that support the exploration of an amended dosing scheme in order to optimize patient tolerability and efficacy outcomes.

Original languageEnglish
Article number1109866
JournalFrontiers in Oncology
Volume13
DOIs
StatePublished - 19 Jan 2023

Keywords

  • alternative dosing strategy
  • clinical study
  • interferon
  • myeloproliferative neoplasm
  • pegylated interferon
  • polycythemia vera
  • ropeginterferon alfa-2b

Fingerprint

Dive into the research topics of 'An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future'. Together they form a unique fingerprint.

Cite this